TriangleZiftomenib Maintenance (NCT06440135)
Ziftomenib Maintenance trial for NPM1-Mutated AML in Remission After Allogeneic Transplant (NCT06440135). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with acute myeloid leukemia with an NPM1 mutation who are in remission after a donor stem cell transplant.
The idea: after the transplant, patients take ziftomenib, a pill once a day, as maintenance. Ziftomenib targets interactions inside the leukemia cells that drive this type of AML. The hope is that it improves outcomes after transplant.
The study looks at safety, effects, and the recommended dose.
This phase 1 study plans 22 patients. At Massachusetts General Hospital in Boston, Zachariah DeFilipp leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.